The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 12, 2025

Filed:

Nov. 25, 2020
Applicant:

Novartis Ag, Basel, CH;

Inventors:

Aida Abujoub, Winchester, MA (US);

John Blankenship, Acton, MA (US);

Attilio Bondanza, Basel, CH;

Jennifer Brogdon, Sudbury, MA (US);

Dexiu Bu, Melrose, MA (US);

Serena De Vita, Brookline, MA (US);

Glenn Dranoff, Sudbury, MA (US);

Boris Engels, Arlington, MA (US);

Tony Fleming, Stow, MA (US);

Brian Walter Granda, Salisbury, MA (US);

Michael R. Greene, Groton, MA (US);

Carla Patricia Guimaraes, Boston, MA (US);

Anniesha Hack, East Hanover, MA (US);

Brian Holmberg, Somerville, MA (US);

Connie Hong, Somerville, MA (US);

Lu Huang, West Roxbury, MA (US);

Olja Kodrasi, Quincy, MA (US);

Joni Waiee Lam, Somerville, MA (US);

Hyungwook Lim, Cambridge, MA (US);

Elizabeth Dorothy Pratico, East Boston, MA (US);

Andrew Price, Cambridge, MA (US);

Akash Sohoni, Cambridge, MA (US);

Andrew Marc Stein, Cambridge, MA (US);

Louise Treanor, Cambridge, MA (US);

Chonghui Zhang, Cambridge, MA (US);

Xu Zhu, Cambridge, MA (US);

Assignee:

Novartis AG, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4215 (2025.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2878 (2013.01); C12N 5/0636 (2013.01); A61K 2039/505 (2013.01); A61K 2239/29 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01);
Abstract

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.


Find Patent Forward Citations

Loading…